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Poly-L-lactic acid (Sculptra, Sanofi Aventis,
Bridgewater, NJ) is a gel polymer made of poly-L-
lactic acid microspheres and water suspended in a
mannitol and carboxymethyl cellulose suspension.1
This injectable tissue filler has been used for
correction of lipoatrophy in HIV patients as well as
for cosmetic purposes since its US Food and
Drug Administration approval in 2004. The mecha-
nism of action involves induction of a subclinical
inflammatory response that stimulates fibroblast
proliferation and collagen formation, ultimately
leading to a progressive increase in volume of the
dermis and subcutaneous tissues.2 Late-onset
immune-mediated adverse effects associated with
the use of poly-L-lactic acid can appear years after the
initial injection with reported range of 6 to
60 months.3 These effects include inflammatory
nodules, papules, and edema. Previous reports of
adverse effects associated with poly-L-lactic acid
identify a maximum of 60 months before develop-
ment of a subcutaneous nodule.3 These adverse
effects can cause significant distress for patients, as
the erythema, edema or nodules that can result may
cause cosmetic disfigurement and mimic an
infectious process, necessitating, at times, extensive
workup including biopsy. Here, we present a case of
granuloma formation that appeared more than
70 months after treatment, surpassing the previously
reported maximum latency of 60 months for poly-L-
lactic acid and long surpassing the 2-year duration
that the product is purported to last in the tissues.1 To
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erest to declare.period for development of a subcutaneous nodule
with foreign body reaction observed with poly-L-
lactic acid. Practitioners should be aware of the
extent of adverse events associated with procedural
complications to adequately inform their patients,
provide the highest standard of care, and maintain
awareness of this etiology in their differential
diagnosis for patients presenting with facial nodules
of unknown etiology, even if poly-L-lactic acid
exposure was several years prior.
CASE
A 48-year-old immunocompetent woman pre-
sented with a solitary visible noninflammatory
nodule on her right temple, which at the time of
presentation had been present for 2 months. The
nodule was firm and indurated, without erythema,
tenderness, fluctuance, edema, or ulceration. The
patient was afebrile, and review of systems was
otherwise negative. Her medical history was
unremarkable, and her only known allergy was to
penicillin. The patient had received a series of
injections of poly-L-lactic acid bilaterally in the
temporal and cheek regions for the indication of
lipoatrophy secondary to aging. Her history of
poly-L-lactic acid exposure began 7 years prior with
injection in the temporal and cheek areas, with 3
injections of 2.5 mL of poly-L-lactic acid in 6 mL
dilution to each side spaced monthly. She also
received an additional 2.15 mL of injections bilater-
ally to the same regions 70 months (approximately
5.8 years) before nodule formation. The dilution of
this round of poly-L-lactic acid injection was 5 mLCorrespondence to: Molly Storer, MS, Department of Dermatology,
55 Fruit Street, BAR 622, Boston, MA, 02114. E-mail: mstorer1@
partners.org.
JAAD Case Reports 2016;2:54-6.
2352-5126
 2015 by the American Academy of Dermatology, Inc. Published
by Elsevier, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
http://dx.doi.org/10.1016/j.jdcr.2015.11.017
Fig 1. Granulomatous inflammation to polarizable foreign body material consistent with
poly-L-lactic acid. (A, Hematoxylin-eosin stain, original magnification, 3200; B, Polarization
microscopy; original magnification, 3200.)
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lidocaine). She received injections of botulinum
toxin A and hyaluronic acid after her last poly-L-
lactic acid treatment and before the development of
the temporal nodule. However, none of these other
treatments were on or near the temporal regions.
Ultimately, the time from last transdermal poly-L-
lactic acid injection to the time the nodule was first
noted by the patient was 2,113 days (70.4 months).
Notably, the same amount of product was
administered to both sides of the face, and the
patient did not recall any other external factors that
would cause a difference in the sides of her face (eg,
unequal pressure, massage, or history of trauma to
one side).
Histopathologic analysis of the lesion on the
temple, including analysis under polarized light
(Fig 1), showed a subcutaneous foreign body
granuloma compatible with foreign body reaction to
poly-L-lactic acid. Results of periodic acideSchiff
stain, Gram stain, and fungal and bacterial cultures
for the presence of organisms were negative. At her
follow-up visit, the patient reported that another
physician treated the nodule once with intralesional
kenalog, and the patient was uncertain of what
dosage was used. The nodule resolved over a period
ofmonths, and it was unclear as towhether or towhat
extent the intralesional kenalog played a role in this
resolution versus timealone. Since the initial temporal
granuloma formation, she has had 2 additional
nodules form in the cheek areas in locations of
previous injection sites of poly-L-lactic acid (also in
the sameperiodover 70months),which also resolved
over a period of months without further intervention.
DISCUSSION
Late-onset granulomatous reactions to poly-L-
lactic acid have been reported since the approval
of poly-L-lactic acid for lipoatrophy secondary
to aging and antiretroviral treatment for HIV.Suggested mechanisms for the development of these
granulomas include local clustering of poly-L-lactic
acid most commonly because of inadequatemassage
of the area after injection and incorrect depth of
injection. The reason these lesions develop years
after injection remains unclear. Cases of late-onset
granuloma formation are reported primarily in
hypermobile areas such as the nasolabial folds,
glabella, and lips.3,4 The temporal region, where a
late-onset granuloma developed in this case, is not
classically considered hypermobile. However, this
region does move during chewing and talking and
perhaps the qualities and behavior of this region as a
cosmetic focus warrant further study. The dilution of
the product in 5 mL of bacteriostatic water and
lidocaine was adequate to prevent granuloma
formation as outlined by safety and efficacy reviews
of poly-L-lactic acid.5 However, some physicians
found decreased incidence of granuloma formation
with increased dilutions.6 Histopathology confirmed
that the depth of injection was indeed in the correct,
subcutaneous plane. Suture granulomas occurring
after abdominal surgery have appeared as long as
12 years after surgery.7 Because of the similarity in
chemical composition of poly-L-lactic acid and
surgical sutures, a longer extent of granuloma
latency may theoretically be considered for cosmetic
dermatologic procedures. This patient experienced
clinical resolution of the granulomas. Although she
was treated with an intralesional steroid, it was
unclear whether or to what extent this actually
provided clinical benefit in terms of resolution,
especially given that she also had other granulomas
that later resolved without any treatment. This case
of the longest yet reported latency period for
development of subcutaneous nodules with foreign
body reaction observed with poly-L-lactic acid serves
to raise awareness of a broader expected time course
for complications associated with poly-L-lactic acid
injection procedures. With increased awareness,
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56 Storer et alpractitioners can better inform patients of the range
of possible complications and can broaden their
differential diagnosis for patients presenting for
facial nodules of unknown etiology, even if poly-L-
lactic acid exposure was several years prior.
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